This study is a proposal for a best practice-based approach based on stakeholder assessment.
As indicated by the authors [Sabine Vogler (GÖ FP), Nina Zimmermann GÖ FP), Katharina Habimana (GÖ FP)] in the Background sector of the study, EU Member States have been struggling to address the challenge of reconciling different, partially conflicting health and non-health policy objectives related to the reimbursement of medicines: timely patient access and equity, cost-containment and sustainable funding, and granting reward for innovation to the pharmaceutical industry. In the European Union, there is, as the High Level Pharmaceutical Forum welcomed, the development of a shared understanding that pricing and reimbursement policies need to balance these objectives.
Source
European Commission
